Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells

Bortezomib is a proteasome inhibitor used for the treatment of relapsed/refractory multiple myeloma (MM). However, intrinsic and acquired resistance to bortezomib has already been observed in MM patients. In a previous report, we demonstrated that changes in the expression of mitochondrial genes lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, In-Sung, Jeong, Yu Jeong, Jeong, Seung Hun, Heo, Hye Jin, Kim, Hyoung Kyu, Lee, Sung Ryul, Ko, Tae Hee, Youm, Jae Boum, Kim, Nari, Ko, Kyung Soo, Rhee, Byoung Doo, Han, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809360/
https://www.ncbi.nlm.nih.gov/pubmed/24158003
http://dx.doi.org/10.1038/emm.2013.104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809360/
https://www.ncbi.nlm.nih.gov/pubmed/24158003
http://dx.doi.org/10.1038/emm.2013.104

Ejemplares similares